Earlier signal
in the ICU.
Three steps. One continuous signal.
Vitals, labs, treatments and imaging stream in continuously from your existing systems via FHIR, HL7, and proprietary adapters.
Streams fuse into a single state. Per-patient baselines are learned from the first hours of admission : your model of this patient, not a population average.
Risk trajectories appear inside your clinical workflow : not next to it, not on a separate screen.
Sepsis first. Then more.
Lead use case: sepsis. Secondary use cases (in development) include cardiovascular deterioration, post-surgical complications, and multi-organ failure progression.
Real-world evidence generation.
Anali-X is currently in retrospective feasibility study with a hospital partner. The study is designed to characterize lead-time, signal stability, and clinical usability. Publication of feasibility findings is targeted Q4 2026, contingent on study progress. Prospective pilot conversations are open with selected EU sites.
In development under MDR.
Anali-X is in development under the EU Medical Device Regulation (MDR) framework as a Class IIb clinical decision support tool. Our quality system targets ISO 13485 certification. Anali-X is not currently CE-marked and is not approved for diagnostic use.